ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.76
0.00%
US Dollar vs AUD
1.49165
0.00%
Bitcoin
67,101.12
0.24%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Tenax Therapeutics Inc (TENX)

  7. Tenax Therapeutics Inc (TENX) News

TENX

Tenax Therapeutics (TENX)

Tenax Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TENX
DateTimeSourceHeadlineSymbolCompany
15/05/202406:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TENXTenax Therapeutics Inc
14/05/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
14/05/202422:00GlobeNewswire Inc.Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:TENXTenax Therapeutics Inc
30/04/202421:30GlobeNewswire Inc.Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
09/04/202422:30GlobeNewswire Inc.Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”NASDAQ:TENXTenax Therapeutics Inc
28/03/202423:30GlobeNewswire Inc.Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsNASDAQ:TENXTenax Therapeutics Inc
12/03/202423:30GlobeNewswire Inc.Tenax Therapeutics to Present at the 36th Annual Roth ConferenceNASDAQ:TENXTenax Therapeutics Inc
01/03/202401:00GlobeNewswire Inc.Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024NASDAQ:TENXTenax Therapeutics Inc
27/02/202408:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
27/02/202408:31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
24/02/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
22/02/202408:32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
22/02/202408:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
21/02/202408:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
21/02/202400:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
21/02/202400:30GlobeNewswire Inc.Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanNASDAQ:TENXTenax Therapeutics Inc
17/02/202403:28Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
16/02/202411:36Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TENXTenax Therapeutics Inc
15/02/202406:58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TENXTenax Therapeutics Inc
14/02/202408:32Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
13/02/202408:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
10/02/202409:00Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:TENXTenax Therapeutics Inc
09/02/202408:51Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
09/02/202400:16GlobeNewswire Inc.Tenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingNASDAQ:TENXTenax Therapeutics Inc
08/02/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TENXTenax Therapeutics Inc
08/02/202412:01GlobeNewswire Inc.Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
07/02/202401:20Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TENXTenax Therapeutics Inc
07/02/202400:56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENXTenax Therapeutics Inc
07/02/202400:30GlobeNewswire Inc.Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)NASDAQ:TENXTenax Therapeutics Inc
03/02/202409:24Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:TENXTenax Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TENX

Your Recent History

USOTC
NPCDF
Nippon Commercial Develo... (PK)
COIN
$ICONSUSD
$ICONS Token
BIT
F14239
Vontobel Financial Produ...
COIN
BETTYGBP
COIN
BBCTGBP
ASX
CSRCC
AMEX
TYTE
KOSPI
001510
SK Securities
BIT
F14619
Vontobel Financial Produ...
EU
IWESE
Index
AMEX
IBDP
iShares iBonds Dec 2024 ...
LSE
ERN
Epic Reconstruction
COIN
UNIIETH
UNII
COIN
JBYBTC
LSE
SYP3
Etf 3x S Jpy L�
COIN
XAUEUR
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved